Volume 20 Supplement 1
American Diabetes Association: Clinical Practice Recommendations 1997

POSITION STATEMENT

Standards of Medical Care for Patients With Diabetes Mellitus

American Diabetes Association

Diabetes is a chronic illness that requires continuing medical care and education to prevent acute complications and to reduce the risk of long-term complications. People with diabetes should receive their treatment and care from a physician-coordinated team. Such teams include, but are not limited to, physicians, nurses, dietitians, and mental health professionals with expertise and a special interest in diabetes.

The following standards define basic medical care for people with diabetes. These standards are not intended to preclude more extensive evaluation and management of the patient by other specialists as needed.

These standards of diabetes care seek to provide:

1. Physicians and other health care professionals who treat people with diabetes with a means to

• Set treatment goals
• Assess the quality of diabetes treatment provided
• Identify areas where more attention or self-management training is needed
• Define timely and necessary referral patterns to appropriate specialists

2. People with diabetes with a means to

• Assess the quality of medical care they receive
• Develop expectations for their role in the medical treatment
• Compare their treatment outcomes to standard goals

For more detailed information, refer to Medical Management of Insulin-Dependent (Type I) Diabetes and Medical Management of Non-Insulin-Dependent (Type II) Diabetes.

GENERAL PRINCIPLES -- Persistent hyperglycemia is the hallmark of all forms of diabetes. Treatment aimed at lowering blood glucose levels to or near normal in all patients is mandated by the following proven benefits:

1. The danger of acute decompensation due to diabetic ketoacidosis or hyperosmolar hyperglycemic nonketotic syndrome, with their accompanying morbidity and mortality, is markedly reduced.

2. The symptoms of blurred vision are alleviated, and the risk of polyuria, polydipsia, fatigue, weight loss with polyphagia, vaginitis, or balanitis may be decreased.

3. The risks of development or progression of diabetic retinopathy, nephropathy, and neuropathy are all greatly decreased. It is possible that these complications may even be prevented by early normalization of metabolic status.

4. Near normalization of blood glucose has been demonstrated to be associated with a less atherogenic lipid profile.

Achieving near normal or normal blood glucose levels in patients with many types of diabetes requires comprehensive training in self-management and, for most individuals, intensive treatment programs. Such programs include the following components according to individual patient need:

• Frequent self monitoring of blood glucose (SMBG)
• Meticulous attention to meal planning
• Regular exercise
• Physiologically based insulin regimens, i.e., multiple daily injections of rapid- (e.g., lispro), short- (e.g., regular), intermediate- (e.g., NPH or lente), or long-acting (e.g., ultralente) insulins or continuous subcutaneous insulin infusion, in type I and some type II patients
• Less-complex insulin regimens or oral glucose lowering agents in some type II patients
• Instruction in the prevention and treatment of hypoglycemia and other acute and chronic complications
• Continuing education and reinforcement
• Periodic assessment of treatment goals

To be effective, treatment programs require ongoing support from the clinical care team.

SPECIFIC GOALS OF TREATMENT

Type I diabetes
Setting individual patient glycemic targets should take into account the results of prospective randomized clinical trials, most notably the Diabetes Control and Complications Trial (DCCT). This trial conclusively demonstrated that in patients with type I diabetes the risk of development or progression of retinopathy, nephropathy, and neuropathy is reduced 50�75% by intensive treatment regimens when compared with conventional treatment regimens. These benefits were observed with an average hemoglobin A_1c of 7.2% in intensively treated groups of patients compared with 9.0% in conventionally treated groups of patients. The reduction in risk of these complications correlated continuously with the reduction in hemoglobin A_1c produced by intensive treatment. This relationship implies that complete normalization of glycemia levels may prevent complications. The nondiabetic reference range for the hemoglobin A_1c in the DCCT was 4.0 to 6.0. Because glycated hemoglobin values differ in different laboratories, diabetes treatment teams should adjust their glycated hemoglobin values to account for local differences in assay methodology and nondiabetic reference ranges.

Self-monitoring blood glucose targets in the DCCT were 70�120 mg/dl (3.9�6.7 mmol/l) before meals and at bedtime and <180 mg/dl (<10.0 mmol/l) when measured 1 1/2 to 2 h postprandially. However, these goals were associated with a threefold increased risk of severe hypoglycemia. Therefore, it may be appropriate to increase these targets (e.g., 80�120 mg/dl [4.4�6.7 mmol/l] before meals and 100�140 mg/dl [5.6�7.8 mmol/l] at bedtime) (Table 1). These targets should be further adjusted in patients with a history of recurrent severe or unrecognized hypoglycemia.

Individual treatment goals should take into account the patient's capacity to understand and carry out the treatment regimen, the patient's risk for severe hypoglycemia, and other patient factors that may increase risk or decrease benefit (e.g., very young or old age, end-stage renal disease, advanced cardiovascular or cerebral vascular disease, or other coexisting diseases that will materially shorten life expectancy).

The desired outcome of glycemic control in type I diabetes is to lower glycated hemoglobin (or any equivalent measure of chronic glycemia) so as to achieve maximum prevention of complications with due regard for patient safety. To achieve these goals with intensive management, the following may be necessary:

• Frequent SMBG (at least 3 or 4 times/day)
• Nutritional counseling
• Training in self-management and problem solving
• Possible hospitalization for initiation of therapy

In situations where resources are unavailable or insufficient, referral to a diabetes care team for consultation and/or comanagement is recommended.

Type II diabetes
In type II diabetes considerable epidemiological evidence exists for a relationship between microvascular disease and hyperglycemia similar to that proven for type I diabetes. A randomized trial similar in design to the DCCT but involving fewer subjects (110 vs. 1,440) showed that improved glucose control, to levels mimicking those in the DCCT, resulted in a comparable reduction in microvascular complications in lean Japanese patients with type II diabetes. It is reasonable to expect that therapy that achieves glycemic goals similar to those in the DCCT will provide similar benefits with regard to long-term microvascular and neurological complications. There are some observational studies showing fewer cardiovascular events and less mortality in better controlled type II diabetes; however, no randomized studies have been completed to support these findings.

When setting treatment goals for type II diabetes, the same individual patient characteristics should be considered as for type I diabetes: the patient's capacity to understand and carry out the treatment regimen, the patient's risk for severe hypoglycemia, and other patient factors that may increase risk or decrease benefit (e.g., advanced age, end-stage renal disease, advanced cardiovascular or cerebrovascular disease, or other coexisting diseases that will materially shorten life expectancy).

Type II diabetes treatment methods should emphasize diabetes management through medical nutrition therapy, exercise, and weight reduction, supplemented when indicated by oral agents and/or insulin. When insulin treatment is needed, large doses may be required to reach these glycemic targets in some patients, especially in obese insulin-resistant patients. There is less certainty that the risk-to-benefit ratio of intensive insulin treatment is as favorable in type II patients as in type I patients.

INITIAL VISIT

Medical history
The comprehensive medical history can uncover symptoms that will help establish the diagnosis in the patient with previously unrecognized diabetes. If the diagnosis of diabetes has already been made, the history should confirm the diagnosis, review the previous treatment, evaluate the past and present degree of glycemic control, determine the presence or absence of the chronic complications of diabetes, assist in formulating a management plan, and provide a basis for continuing care. Elements of the medical history of particular concern in patients with diabetes include:

• Symptoms, results of laboratory tests, and special examination results related to the diagnosis of diabetes
• Prior glycated hemoglobin records
• Eating patterns, nutritional status, and weight history; growth and development in children and adolescents
• Details of previous treatment programs, including nutrition and diabetes self-management training
• Current treatment of diabetes, including medications, meal plan, and results of glucose monitoring and patients' use of the data
• Exercise history
• Frequency, severity, and cause of acute complications such as ketoacidosis and hypoglycemia
• Prior or current infections, particularly skin, foot, dental, and genitourinary
• Symptoms and treatment of chronic complications associated with diabetes: eye; kidney; nerve; genitourinary (including sexual), bladder, and gastrointestinal function; heart; peripheral vascular; foot; and cerebrovascular
• Other medications that may affect blood glucose levels
• Risk factors for atherosclerosis: smoking, hypertension, obesity, dyslipidemia, and family history
• History and treatment of other conditions including endocrine and eating disorders
• Family history of diabetes and other endocrine disorders
• Gestational history: hyperglycemia, delivery of an infant weighing >9 lb, toxemia, stillbirth, polyhydramnios, or other complications of pregnancy
• Lifestyle, cultural, psychosocial, educational, and economic factors that might influence the management of diabetes

Physical examination
A physical examination should be performed during the initial evaluation. People with diabetes have a high risk of developing eye, kidney, foot, nerve, cardiac, and vascular complications. Patients with type I diabetes have an increased frequency of autoimmune disorders, especially thyroid disease. All individuals with poorly controlled diabetes are at increased risk for infections. Children with poorly controlled diabetes may have delayed growth and maturation. Therefore, certain aspects of the detailed physical examination should be performed. These include:

• Height and weight measurement (and comparison to norms in children and adolescents)
• Sexual maturation staging (during peripubertal period)
• Blood pressure determination (with orthostatic measurements when indicated) and comparison to age-related norms
• Ophthalmoscopic examination (preferably with dilation)
• Oral examination
• hyroid palpation
• Cardiac examination
• Abdominal examination (e.g., hepatomegaly)
• Evaluation of pulses (by palpation and auscultation)
• Hand/finger examination
• Foot examination
• Skin examination (including insulin- injection sites)
• Neurological examination

The clinician should also be alert for signs of diseases that can cause secondary diabetes, e.g., hemochromatosis, pancreatic disease, and endocrine disorders such as acromegaly, pheochromocytoma, and Cushing's syndrome.

Laboratory evaluation
Blood glucose testing and urine ketone testing should be available in the office for immediate use as needed. In addition, each patient should undergo laboratory tests that are appropriate to the evaluation of the individual's general medical condition. Certain tests should be obtained to establish the diagnosis of diabetes, determine the degree of glycemic control, and define associated complications and risk factors. These include:

• Fasting plasma glucose (a random plasma glucose may be obtained in an undiagnosed symptomatic patient for diagnostic purposes)
• Glycated hemoglobin
• Fasting lipid profile: total cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, and low-density lipoprotein (LDL) cholesterol
• Serum creatinine in adults; in children if proteinuria is present
• Urinalysis: glucose, ketones, protein, sediment
• Determination for microalbuminuria (e.g., timed specimen or the albumin/creatinine ratio) in pubertal patients who have had diabetes at least 5 years and all patients with type II diabetes
• Urine culture, if sediment is abnormal or symptoms are present
• Thyroid function test(s) when indicated
• Electrocardiogram (in adults)

Management plan
A complete, organized medical record system is essential to provide ongoing care of people with diabetes. The records always must be accessible to the diabetes treatment team and organized so that they not only document what has occurred but serve as a reminder of what should be done at appropriate intervals.

The management plan should be formulated as an individualized therapeutic alliance among the patient and family, the physician, and other members of the health care team skilled in the management of diabetes to achieve the desired level of diabetes control. Patient self-management should be emphasized. To this end, the management plan should be formulated in collaboration with the patient, and the plan should emphasize the involvement of the patient in problem solving as much as possible. A variety of strategies and techniques should be employed to provide adequate education and development of problem-solving skills in the various aspects of diabetes management.

When formulating this management plan, consideration should be given to the age, school or work schedules and conditions, physical activity, eating patterns, social situation and personality, cultural factors, and presence of complications of diabetes or other medical conditions. Implementation of the management plan requires that each aspect be understood and agreed upon by the patient and the care providers and that the goals and treatment plan are reasonable. The management plan should include:

• Statement of short- and long-term goals
• Medications (insulin, oral glucose-lowering agents, glucagon, antihypertensive and lipid-lowering agents, other endocrine drugs, and other medications)
• Individualized nutrition recommendations and instructions, preferably by a registered dietitian familiar with the components of diabetesmedical nutrition therapy
• Recommendations for appropriate lifestyle changes (e.g., exercise, smoking cessation)
• Patient and family education for self-management that is consistent with the National Standards for Diabetes Self-Management Education Programs, preferably provided by a Certified Diabetes Educator
• Monitoring instructions: self-monitoring of blood glucose (SMBG), urine ketones, and use of a record system. Frequency of SMBG should be individualized according to clinical circumstances, the form of treatment employed, and the response to treatment. Urine glucose may be considered as an alternative only if the patient is unable or unwilling to perform blood glucose testing or if the only goal is avoidance of symptomatic hyperglycemia
• Annual comprehensive dilated eye and visual examinations by an ophthalmologist or optometrist for all patients age 12 and over who have had diabetes for 5 years, all patients over the age of 30, and any patient with visual symptoms and/or abnormalities
• Consultation for podiatry services as indicated
• Consultation for specialized services as indicated
• Agreement on continuing support and follow-up and return appointments
• Instructions on when and how to contact the physician or other members of the health care team when the patient has not been able to solve problems and for management of acute problems
• For women of childbearing age, discussion of contraception and emphasis on the necessity of optimal blood glucose control before conception and during pregnancy
• Dental hygiene

See Table 3 for a summary of the initial visit.

CONTINUING CARE

Continuing care is essential in the management of every patient with diabetes. At each visit, the patient's progress in achieving treatment goals should be evaluated by the health care team, and problems that have occurred should be reviewed. If goals are not being met, the management plan needs to be revised and/or the goals need to be reassessed.

Visit frequency
The frequency of patient visits depends on

• the type of diabetes
• the blood glucose goals and the degree to which they are achieved
• changes in the treatment regimen
• the presence of complications of diabetes or other medical conditions.

Patients initiating insulin therapy or having a major change in their insulin program may need to be in contact with their care provider as often as daily until glucose control is achieved, the risk of hypoglycemia is low, and the patient is competent and comfortable implementing the treatment plan. Some patients may require hospitalization for initiation or change of therapy.

Patients beginning treatment with nutrition therapy or oral glucose-lowering agents may need to be contacted as often as weekly until reasonable glucose control is achieved and the patient is competent to conduct the treatment program. Regular visits should be scheduled for all patients with diabetes. Insulin-treated patients should generally be seen at least quarterly and other patients quarterly or semiannually until achievement of all treatment goals. Thereafter, the frequency of visits may be decreased as long as the patient continues to achieve all treatment goals. (More frequent contact also may be required if the patient is undergoing intensive insulin therapy, not meeting glycemic or blood pressure goals, or has evidence of progression in microvascular or macrovascular complications.) Patients must be taught to recognize problems with their glucose control as indicated by their records of self-monitoring of blood glucose and to promptly report concerns to the health-care team to clarify and strengthen their self-management skills. They also should be taught to recognize early signs and symptoms of acute and chronic complications and to report these immediately. Severe hypoglycemic reactions requiring the assistance of another person must be reported as soon as possible.

Medical history
An interim history should be obtained at each visit and should include:

• frequency, causes, and severity of hypoglycemia or hyperglycemia
• results of SMBG
• adjustments by the patient of the therapeutic regimen
• problems with adherence
• symptoms suggesting development of the complications of diabetes
• other medical illnesses
• current medications
• psychosocial issues
• lifestyle changes

Physical exam
The quarterly or semi-annual exam should include:

• height (until maturity)
• weight
• blood pressure
• sexual maturation (periodically in peripubertal patients)
• funduscopy (referral if retinopathy detected)
• foot examination

If abnormalities are identified, more frequent follow-up may be required.

Comprehensive dilated eye and visual examinations should be performed annually by an ophthalmologist or optometrist who is knowledgeable and experienced in the management of diabetic retinopathy for all patients age 12 and over who have had diabetes for 5 years, all patients over the age of 30, and any patient with visual symptoms and/or abnormalities.

Laboratory evaluation
A glycated hemoglobin (GHb) determination should be performed routinely in all patients with diabetes, first to document the degree of glycemic control at initial assessment, then as part of continuing care. Since GHb reflects a mean glycemia over the preceding 2�3 months, measurement approximately every 3 months is required to determine whether a patient's metabolic control has remained continuously within the target range. Thus, regular measurements of GHb permit detection of departures from the target range in a timely fashion. For any individual patient, the frequency of GHb testing should be dependent on the treatment regimen employed and on the judgment of the clinician. In the absence of well-controlled studies that suggest a definite testing protocol, expert opinion recommends GHb testing at least one or two times a year in patients with a history of stable glycemic control and quarterly assessments in patients whose therapy has changed or who are in poor control.

Adult patients with diabetes should be tested for lipid disorders annually with a fasting serum cholesterol, triglyceride, HDL cholesterol and calculated LDL cholesterol. If all values are within acceptable limits, the clinician may consider obtaining this lipid profile less frequently. Acceptable, borderline, and high-risk lipid levels for adults are shown in Table 2. Borderline or abnormal values should be repeated for confirmation. Abnormal values requiring institution of therapy should be repeated following the National Cholesterol Education Program recommendations. Lipid values should be reevaluated in the presence of a macrovascular event.

A lipid profile should be performed on children older than 2 years, after diagnosis of diabetes and when glucose control has been established. Borderline or abnormal values should be repeated for confirmation. If values fall within accepted risk levels, assessment should be repeated every 5 years. Abnormal values requiring institution of therapy should be repeated following the National Cholesterol Education Program recommendations.

Routine urinalysis should be performed yearly in adults. If positive for protein, a quantitative measure is frequently helpful in the development of a treatment plan. If the urinalysis is negative for protein, a test for the presence of microalbumin is necessary. Screening in individuals with type I diabetes should begin with puberty and after 5 years' duration. Because of the difficulty in precise dating of the onset of type II diabetes, such screening should begin at the time of diagnosis. Screening for microalbuminuria can be performed by three methods:

• measurement of the albumin to creatinine ratio in a random, spot collection.
• 24-h collection with creatinine, allowing the simultaneous measurement of creatinine clearance
• timed (e.g., 4-h or overnight) collection

The first method is often found to be the easiest in an office setting and generally provides accurate information; first-void or other morning collections are preferred because of the known diurnal variation in albumin excretion but if this timing cannot be used, uniformity of timing for different collections in the same individual should be employed.

Management plan
The management plan should be reviewed at each regular visit to determine progress in meeting goals and to identify problems. This review should include the control of blood glucose levels, assessment of complications, control of blood pressure, control of dyslipidemia, nutrition assessment, frequency of hypoglycemia, adherence to all aspects of self-care, evaluation of the exercise regimen, follow-up of referrals, and psychosocial adjustment. In addition, knowledge of diabetes and self-management skills should be reassessed at least annually. Continuing education should be provided or encouraged.

See Table 4 for a summary of continuing care.

SPECIAL CONSIDERATIONS

Children and adolescents
Approximately three-quarters of all newly diagnosed cases of type I diabetes occur in individuals below the age of 18 years. Care of this group requires integration of diabetes management with the complicated physical and emotional growth needs of children, adolescents, and their families. Diabetes care for children of this age group should be provided by a team that can deal with these special medical, educational, nutritional, and behavioral issues.

At the time of initial diagnosis, it is extremely important to establish the goals of care and to begin diabetes self-management training. A firm educational base should be provided so that the individual and family can become increasingly independent in the self-management of diabetes. Glycemic goals may need to be modified to take into account the fact that most children under the age of 6 or 7 years have a form of "hypoglycemic unawareness," in that they lack the cognitive capacity to recognize and respond to hypoglycemic symptoms. Intercurrent illnesses are more frequent in young children. Sick-day management rules must be established and taught to prevent hospitalization. A nutritional assessment should be performed at diagnosis and at least annually by an individual experienced with the nutritional needs of the growing child and the behavioral issues that impact on adolescent diets. Caution must be exercised to avoid over-aggressive dietary manipulation in the very young. Assessment of lifestyle needs should be accompanied by possible modifications of the diabetic regimen. For example, an adolescent who requires more flexibility might be switched to a 3 or 4 insulin injection program when needed.

A major issue deserving emphasis in this age group is that of "compliance." No matter how sound the medical regimen, it can only be as good as the ability of the family and/or individual to implement it. Health care providers who care for children and adolescents must therefore be capable of evaluating the behavioral, emotional, and psychosocial factors that interfere with implementation and then work with the individual and family to resolve problems that occur and/or to modify goals as appropriate.

Information should be supplied to the school so that school personnel are aware of the diagnosis of diabetes in the student and the signs/symptoms and treatment of hypoglycemia. It is desirable that blood glucose testing be performed at school prior to lunch and when signs/symptoms of abnormal blood glucose levels are present.

Referral for diabetes management
For a variety of reasons, it may not be possible to provide care that meets these standards or achieves the desired goals of treatment. In such instances, the patient should be referred to a diabetologist/endocrinologist-led diabetes treatment team for consultation and/or comanagement.

Intercurrent illness
The stress of illness frequently aggravates glycemic control and necessitates more frequent monitoring of blood glucose and urine ketones. Marked hyperglycemia requires temporary adjustment of the treatment program, and, if accompanied by ketosis, frequent interaction with the diabetes care team. The patient treated with oral hypoglycemic agents or diet alone may temporarily require insulin. Adequate fluid and caloric intake must be assured. Infection or dehydration is more likely to necessitate hospitalization of the person with diabetes than the person without diabetes. The hospitalized patient should be treated by a physician with expertise in the management of diabetes.

Diabetic ketoacidosis and hyperosmolar hyperglycemic nonketotic syndrome
These conditions represent decompensation in diabetic control and require immediate treatment. Careful evaluation of the patient for associated or precipitating events must be undertaken (e.g., infection, medications, vascular events), and associated problems must be treated appropriately. Depending on the severity of the illness and available resources, treatment can be initiated in the physician's office, but is best carried out in the emergency room, hospital room, or intensive-care unit. Because of the potential morbidity and mortality of diabetic ketoacidosis and the hyperosmolar hyperglycemic nonketotic syndrome, prompt consultation with a diabetologist/endocrinologist is recommended when the initial clinical and/or biochemical state is markedly abnormal, when the initial response to standard therapy is unsatisfactory, or when metabolic complications or cerebral edema occur. Recurrence of diabetic ketoacidosis demands a detailed psychosocial and educational evaluation by a diabetes specialist.

Severe or frequent hypoglycemia
The occurrence of severe, frequent, or unexplained episodes of hypoglycemia may be due to a number of factors such as defective counterregulation, hypoglycemia unawareness, insulin dose errors, and excess alcohol intake. This may also be a consequence of the therapeutic regimen and always requires evaluation of both the management plan and its execution by the patient. Family members and close associates of patients using insulin should be taught to use glucagon.

The successful accomplishment of these goals requires more frequent patient contacts during readjustment of the treatment program and patient/family reeducation.

PREGNANCY
To reduce the risk of fetal malformations and maternal and fetal complications, pregnant women and women planning pregnancy require excellent blood glucose control. These women need to be seen by a physician frequently, must be trained in self-monitoring of blood glucose, and may require specialized laboratory and diagnostic tests. Consultation with an obstetrician, ophthalmologist, and medical specialist in diabetes is indicated before and during pregnancy.

Because of the need for prepregnancy planning and excellent glucose control, every pregnancy in a woman with diabetes should be planned in advance. Therefore any diabetic woman who is not currently attempting to conceive should be informed of and offered acceptable and effective methods of contraception.

RETINOPATHY
Patients with clinically significant macular edema, moderate to severe nonproliferative retinopathy, or any proliferative retinopathy require the prompt care of an ophthalmologist who is knowledgeable and experienced in the management of diabetic retinopathy. (See the American Diabetes Association Position Statement, "Screening for Diabetic Retinopathy," for further discussion.)

HYPERTENSION
Hypertension contributes to the development and progression of chronic complications of diabetes. In patients with type I diabetes, persistent hypertension is often a manifestation of diabetic nephropathy, as indicated by concomitant elevated levels of urinary albumin and, in later stages, by a decrease in the glomerular filtration rate. In patients with type II diabetes, hypertension often is part of a syndrome that also includes glucose intolerance, insulin resistance, obesity, dyslipidemia, and coronary artery disease. Isolated systolic hypertension may occur with long duration of either type of diabetes and is, in part, due to inelasticity of atherosclerotic large vessels. Control of hypertension has been demonstrated to reduce the rate of progression of diabetic nephropathy and reduce the complications of hypertensive nephropathy, cerebrovascular disease, and cardiovascular disease.

General principles
Lifestyle modifications should initially be employed to reduce blood pressure unless hypertension is at an urgent level. Such methods include weight loss, exercise, reduction of dietary sodium, and limiting consumption of alcohol. If lifestyle modifications do not achieve specified goals, medications should be added in a stepwise fashion until blood pressure goals are reached.

Several medications in patients with albuminuria (e.g., angiotensin-converting enzyme [ACE] inhibitors) appear to have selective benefit in patients with diabetes.

Other cardiovascular risk factors, such as smoking, inactivity, and elevated LDL cholesterol levels, should also be treated concomitantly.

Specific goals of treatment
Hypertension traditionally has been defined as a systolic blood pressure >140 mmHg and/or a diastolic blood pressure of >90 mmHg. Most epidemiological studies have suggested that risk due to elevated blood pressure is a continuous function, so these cutoff levels are arbitrary. In the general population, the risks for end-organ damage appear to be lowest when the systolic blood pressure is <120 mmHg and the diastolic is<80 mmHg.

The primary goal of therapy for adults should be to decrease blood pressure to<130/85 mmHg. In children, blood pressure should be decreased to the corresponding 90th percentile values.

For patients with an isolated systolic hypertension of >180 mmHg, the goal is a blood pressure <160 mmHg. For those with systolic blood pressure of 160�179, the goal is a reduction of 20 mmHg. If these goals are achieved and well-tolerated, further lowering to 140 mmHg may be appropriate.

NEPHROPATHY

General principles
Persistent albuminuria in the 30�300 mg/24 h range (microalbuminuria) has been shown to be the earliest stage of diabetic nephropathy. Patients with microalbuminuria will likely progress to clinical albuminuria (>300 mg/24 h) and decreasing glomerular filtration rate (GFR) over a period of years. Once clinical albuminuria occurs, the risk for end stage renal disease (ESRD) is high in type I and significant in type II diabetes. Hypertension usually develops during the stages of micro- or clinical albuminuria and, if untreated, can hasten the progression of renal disease. Over the past several years, a number of interventions have been demonstrated to retard the initial development or rate of progression of renal disease.

Specific goals of treatment
Intensive diabetes management with the goal of achieving near normoglycemia has been proven to delay the onset of microalbuminuria and delay the progression of microalbuminuria to clinical albuminuria in patients with type I diabetes.

Lowering blood pressure in hypertensive individuals to <130/85, by any effective means, should be the goal in hypertensive individuals. A reduction in blood pressure will also decrease the rate of progression of diabetic nephropathy.

Treatment of hypertensive patients with both types of diabetes who have microalbuminuria or clinical albuminuria with ACE inhibitors has been shown to delay progression from microalbuminuria to clinical albuminuria and to slow the decline in GFR in patients with clinical albuminuria. Current data suggest that normotensive patients with clinical albuminuria and normotensive type I patients and some normotensive type II patients with microalbuminuria may also benefit from ACE inhibitors.

Measurement of urine albumin should be done on a 24-h or other timed urine collection. Alternatively, the ratio of albumin to creatinine concentration can be measured in a random urine specimen. There is also marked day-to-day variability in albumin excretion, so that at least 2 of 3 collections done in a 3�6 month period should show elevated levels before designating a patient as having microalbuminuria.

Assessment of the creatinine clearance should be performed using the serum creatinine and formulas that take into account the patient's age, gender, and body size or by measuring creatinine in serum and in a timed urine specimen. The creatinine clearance overestimates GFR so that such methods do not detect an early decline in kidney function.

Repeat timed or overnight urine collections to document treatment effect on albumin excretion and to detect the rare case of a deleterious effect of drug therapy should be obtained periodically. If ACE inhibitors are used, serum potassium levels should also be monitored for the development of hyperkalemia, with an increased frequency of monitoring when there is a progressive decrease in GFR or in patients with hyporeninemic hypoaldosteronism.

Protein restriction to 0.8 g � kg body wt^-1 � day^-1 (~10% of daily calories), the current adult recommended daily allowance for protein, should be instituted with the onset of overt nephropathy. However, it has been suggested that once the GFR begins to fall, further restriction to 0.6 g � kg body wt^-1 � day^-1 may prove useful in slowing the decline of GFR in selected patients. On the other hand, nutrition deficiency may occur in some individuals and may be associated with muscle weakness. Protein-restricted meal plans should be designed by a registered dietitian familiar with all components of the dietary management of diabetes.

Referral to a physician experienced in the care of diabetic renal disease should be considered when the GFR has fallen to either <70 ml � min^-1 � 1.73 m^-2 or when serum creatinine has increased above 2.0 mg/dl (180 �mol/l) or when difficulties occur in management of hypertension or hyperkalemia. (See the American Diabetes Association Position Statement, "Diabetic Nephropathy," for a complete discussion on the treatment of nephropathy.)

CARDIOVASCULAR DISEASE
Evidence of cardiovascular disease such as angina, claudication, decreased pulses, carotid bruits, and electrocardiogram abnormalities requires efforts aimed at correction of contributing risk factors (e.g., obesity, smoking, hypertension, sedentary lifestyle, dyslipidemia, poorly regulated diabetes) in addition to specific treatment of the cardiovascular problem. Daily intake of aspirin has been shown to reduce cardiovascular events in patients with diabetes.

DYSLIPIDEMIA

General principles
Diabetes increases the risk for atherosclerotic vascular disease. This risk is greatest in persons who have other known risk factors (such as dyslipidemia, hypertension, smoking, and obesity). Furthermore, in type II diabetes there is an additional increased risk for obesity and lipid abnormalities independent of the level of glycemic control. A common abnormal lipid pattern in such patients is an elevation of very-low-density lipoprotein (VLDL), a reduction in HDL, and an LDL fraction that contains a greater proportion of small, dense atherogenic LDL particles.

Data about treatment of dyslipidemia in people with diabetes, especially in children, are limited. However, current recommendations from the National Cholesterol Education Program Adult Treatment Panel II report on the general management of elevated cholesterol and triglycerides have set increasingly stringent treatment targets based on the number of cardiovascular risk factors and the presence of coronary heart disease (CHD). Risk factors include age (men >45 years or women >55 years, or premature menopause without estrogen replacement therapy), diabetes mellitus, hypertension, HDL cholesterol <35 mg/dl (0.90 mmol/l), smoking, and a family history of premature CHD. Because diabetes appears to eliminate the protective effect of female gender against CHD, all adults with diabetes are candidates for progressively aggressive therapy.

The following recommendations are designed to achieve two major goals as a result of treatment of dyslipidemia: 1) reducing the risk for development of CHD in people without documented CHD and 2) reducing the risk for progression of CHD or to cause regression in people with known CHD.

A meal plan designed both to lower glucose levels and to alter lipid patterns and regular physical activity are the cornerstones in the management of lipid disorders. The goal of nutrition therapy should focus on three major strategies: weight loss if indicated, increased physical activity, and meal plan recommendations individualized for the patient.

Weight loss is achieved by reducing total caloric and fat intake and by increasing physical activity. Recommendations for increased physical activity, however, need to be made in the context of the patient's history and medical status. The recommendations should detail a frequency, duration, and intensity of exercise. If there is an inadequate response to a trial of nutrition therapy, exercise, and improved glucose control, lipid-lowering pharmacological agents are indicated. See the American Diabetes Association consensus statement "Detection and Management of Lipid Disorders in Diabetes" for a complete discussion of the treatment of lipid disorders.

The primary emphasis in children and adolescents with serum lipid abnormalities should be on glucose control, nutrition therapy, and exercise. Because there are important considerations regarding the efficacy and safety of drug therapy for dyslipidemia in children and adolescents, drug therapy in these individuals should only be undertaken in consultation with a physician experienced in the area of lipid disorders in children.

Specific goals of treatment
The primary goal of therapy for adult patients with diabetes is to lower LDL cholesterol to <130 mg/dl (<3.35 mmol/l). The primary goal of therapy in people with known CHD is to lower the LDL cholesterol to <100 mg/dl (<2.60 mmol/l) and triglycerides to <200 mg/dl (<2.30 mmol/l).

People with diabetes who have triglyceride levels >1,000 mg/dl (>11.3 mmol/l) are at risk of pancreatitis and other manifestations of the hyperchylomicronemic syndrome. These individuals need special, immediate attention to lower triglyceride levels to <400 mg/dl (<4.50 mmol/l). Further reduction to Adult Treatment Panel II goals of <200 mg/dl (<2.30 mmol/l) may be beneficial.

A secondary goal of therapy is to raise HDL cholesterol to >35 mg/dl (>0.90 mmol/l) in men and >45 mg/dl (>1.15 mmol/l) in women.

The primary goal of therapy for children with risk factors in addition to diabetes is to lower LDL cholesterol to <160 mg/dl (<4.15 mmol/1).

NEUROPATHY
Peripheral diabetic neuropathy may result in pain, loss of sensation, and muscle weakness. Autonomic involvement can affect gastrointestinal, cardiovascular, and genitourinary function. Each condition may require special diagnostic testing and consultation with an appropriate medical specialist. Improvement in neuropathy should be sought by increased attention to blood glucose control. Relief can be provided by various medications, alterations in medical nutrition therapy, or specialized procedures.

FOOT CARE
Problems involving the feet may require care by a podiatrist, orthopedic surgeon, vascular surgeon, or rehabilitation specialist experienced in the management of people with diabetes. All patients, especially those with evidence of sensory neuropathy and/or peripheral vascular disease, must be educated about the risk and prevention of foot problems, and this education must be regularly reinforced.

Patients with a history of previous foot lesions, especially those with prior amputations, require preventive foot care and lifelong surveillance preferably by a foot-care specialist. (See the American Diabetes Association Position Statement, "Foot Care in Patients With Diabetes Mellitus," for a complete discussion on foot care.)

Bibliography

1. Weir GC, Nathan DM, Singer DE: Standards of care (Technical Review). Diabetes Care 17:1514�1522, 1994

2. Santiago JV (Ed.): Medical Management of Insulin-Dependent (Type I) Diabetes. 2nd ed. Alexandria, VA, American Diabetes Assoc., 1994

3. Raskin P (Ed.): Medical Management of Non-Insulin-Dependent (Type II) Diabetes. 3rd ed. Alexandria, VA, American Diabetes Assoc., 1994

4. Cryer PE, Fisher JN, Shamoon H: Hypoglycemia (Technical Review). Diabetes Care 17:734�755, 1994

5. American Diabetes Association: Nutrition recommendations and principles for people with diabetes mellitus (Position Statement). Diabetes Care 20 (Suppl. 1):S14�S17, 1997

6. American Diabetes Association: Self-monitoring of blood glucose (Consensus Statement). Diabetes Care 19 (Suppl. 1):S62�S66, 1996

7. Expert Panel on Blood Cholesterol Levels in Children and Adolescents: Treatment recommendations of the national cholesterol education program report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics 89 (Suppl.):525�584, 1992

8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Summary of the second report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 269:3015�3023, 1993

9. Kasiske BL, Kalikl RSN, Ma JZ: Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 118:129�138, 1993

10. American Diabetes Association: Guide to diagnosis and classification of diabetes mellitus and other categories of glucose intolerance (Position Statement). Diabetes Care 20 (Suppl. 1):S21, 1997

11. American Diabetes Association: Gestational diabetes mellitus (Position Statement). Diabetes Care 20 (Suppl. 1):S44� S45, 1997

12. American Diabetes Association: Diabetic nephropathy (Position Statement). Diabetes Care 20 (Suppl. 1):S24�S27, 1997

13. American Diabetes Association: Foot care in patients with diabetes mellitus (Position Statement). Diabetes Care 20 (Suppl. 1):S31�S32, 1997

14. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyosyi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Research and Clinical Practice 28:103�117, 1995

15. Moss SE, Klein R, Klein BEK, Meuer MS: The association of glycemia and cause-specific mortality in a diabetic population. Arch Int Med 154:2473�2479, 1994

16. Andersson DKG, Svardsudd K: Long term glycemic control relates to mortality in type II diabetes. Diabetes Care 18:1534� 1543, 1995

17. Uusitupa MIJ, Niskanen LK, Siitonen O, Voutilainen E, Py�r�l� K: Ten year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia 36:1174�1184, 1993

Originally approved October 1988. Revised in March 1994, corrections October 1994. Revised 1996.
For a technical review on this subject see Diabetes Care 17:1514�1522, 1994.